{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:07:10Z","timestamp":1789664830431,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,18]]},"DOI":"10.7759\/cureus.39191","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:10:55Z","timestamp":1684437055000},"source":"Crossref","is-referenced-by-count":5,"title":["Vancomycin-Induced Hemolytic Anemia"],"prefix":"10.7759","author":[{"given":"Fakeha","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-021-00604-9","article-title":"Cefazolin-induced hemolytic anemia: a case report and systematic review of literature","volume":"26","author":"Mause E","year":"2021","unstructured":"Mause E, Selim M, Velagapudi M. Cefazolin-induced hemolytic anemia: a case report and systematic review of literature. Eur J Med Res. 2021, 26:133. 10.1186\/s40001-021-00604-9","journal-title":"Eur J Med Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14362","article-title":"Drug-induced immune hemolytic anemia associated with anti-vancomycin complicated by a paraben antibody","volume":"58","author":"Gniadek TJ","year":"2018","unstructured":"Gniadek TJ, Arndt PA, Leger RM, Zydowicz D, Cheng EY, Zantek ND. Drug-induced immune hemolytic anemia associated with anti-vancomycin complicated by a paraben antibody. Transfusion. 2018, 58:181-8. 10.1111\/trf.14362","journal-title":"Transfusion"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.73","article-title":"Drug-induced immune hemolytic anemia","volume":"2009","author":"Garratty G","year":"2009","unstructured":"Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009, 2009:73-9. 10.1182\/asheducation-2009.1.73","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1975.03260050038017","article-title":"Penicillin-induced immune hemolytic anemia. Occurrence of massive intravascular hemolysis","volume":"233","author":"Ries CA","year":"1975","unstructured":"Ries CA, Rosenbaum TJ, Garratty G, Petz LD, Fudenberg HH. Penicillin-induced immune hemolytic anemia. Occurrence of massive intravascular hemolysis. JAMA. 1975, 233:432-5. 10.1001\/jama.1975.03260050038017","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01173.x","article-title":"One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm","volume":"47","author":"Johnson ST","year":"2007","unstructured":"Johnson ST, Fueger JT, Gottschall JL. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm. Transfusion. 2007, 47:697-702. 10.1111\/j.1537-2995.2007.01173.x","journal-title":"Transfusion"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000440673","article-title":"Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre","volume":"42","author":"Mayer B","year":"2015","unstructured":"Mayer B, Bartolm\u00e4s T, Y\u00fcrek S, Salama A. Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre. Transfus Med Hemother. 2015, 42:333-9. 10.1159\/000440673","journal-title":"Transfus Med Hemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0257-7","article-title":"Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature","volume":"19","author":"Leicht HB","year":"2018","unstructured":"Leicht HB, Weinig E, Mayer B, Viebahn J, Geier A, Rau M. Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature. BMC Pharmacol Toxicol. 2018, 19:67. 10.1186\/s40360-018-0257-7","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9841097","article-title":"Co-amoxiclav induced immune haemolytic anaemia: a case report","volume":"2020","author":"Karunathilaka HG","year":"2020","unstructured":"Karunathilaka HG, Chandrasiri DP, Ranasinghe P, Ratnamalala V, Fernando AH. Co-amoxiclav induced immune haemolytic anaemia: a case report. Case Rep Hematol. 2020, 2020:9841097. 10.1155\/2020\/9841097","journal-title":"Case Rep Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00615.x","article-title":"Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells","volume":"100","author":"Garratty G","year":"1998","unstructured":"Garratty G, Arndt PA. Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells. Br J Haematol. 1998, 100:777-83. 10.1046\/j.1365-2141.1998.00615.x","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.0958-7578.2004.00481.x","article-title":"Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells","volume":"14","author":"Broadberry RE","year":"2004","unstructured":"Broadberry RE, Farren TW, Bevin SV, et al.. Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells. Transfus Med. 2004, 14:53-7. 10.1111\/j.0958-7578.2004.00481.x","journal-title":"Transfus Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2003.00323.x","article-title":"Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells","volume":"85","author":"Arndt PA","year":"2003","unstructured":"Arndt PA, Leger RM, Garratty G. Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells. Vox Sang. 2003, 85:53. 10.1046\/j.1423-0410.2003.00323.x","journal-title":"Vox Sang"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky RA","year":"2019","unstructured":"Brodsky RA. Warm autoimmune hemolytic anemia. N Engl J Med. 2019, 381:647-54. 10.1056\/NEJMcp1900554","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios GE","year":"2019","unstructured":"Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol. 2019, 102:157-62. 10.1111\/ejh.13187","journal-title":"Eur J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5848","article-title":"Vancomycin spacer-induced hemolysis","volume":"11","author":"Sudhakaran A","year":"2019","unstructured":"Sudhakaran A, Baburaj A, Banerjee K, Essrani R. Vancomycin spacer-induced hemolysis. Cureus. 2019, 11:e5848. 10.7759\/cureus.5848","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill QA","year":"2017","unstructured":"Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017, 177:208-20. 10.1111\/bjh.14654","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08784.x","article-title":"Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study","volume":"154","author":"Garbe E","year":"2011","unstructured":"Garbe E, Andersohn F, Bronder E, et al.. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol. 2011, 154:644-53. 10.1111\/j.1365-2141.2011.08784.x","journal-title":"Br J Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/154700-vancomycin-induced-hemolytic-anemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:51Z","timestamp":1707508911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/154700-vancomycin-induced-hemolytic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.39191","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,18]]}}}